en · de · es · fr · pt
semaglutide-notes.peptides1004.com › Guide › Semaglutide Background And Drug Class — Explained

Semaglutide Background And Drug Class — Explained

By Editorial Desk · published 2025-12-22 · last reviewed 2026-01-05 · Guide

体积排阻色谱 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-01-05. Numbers and descriptions here follow the published literature rather than marketing material.

Semaglutide Background and Drug Class

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.

GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.

结构特征与受体作用机制

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物,其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代,使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸,进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链,该侧链赋予分子与血浆白蛋白结合的能力。

该分子作为 GLP-1 受体的选择性激动剂发挥作用,受体属于 B 类 G 蛋白偶联受体家族,激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞,信号促进葡萄糖依赖性的胰岛素释放,血糖偏低时该作用明显减弱。在胰岛 α 细胞,胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达,相应信号参与食欲调节以及胃排空速率的降低。

Semaglutide at a glance

PropertyValueNotes
Molecular formulaC187H291N45O59Peptide backbone with a C18 fatty diacid side chain
Molecular weightApproximately 4113 DaConsistent with a 31-residue peptide plus linker
AppearanceWhite to off-white powderLyophilized solid; hygroscopic if left open
Solubility classSparingly soluble to soluble in waterVaries with pH and ionic strength
Typical analytical methodReversed-phase HPLC with UV detectionOften paired with mass spectrometry for identity

储存条件与分析表征方法

市售注射用制剂通常要求在二至八摄氏度冷藏保存,并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数,具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数,因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器,以减少肽类在塑料或玻璃表面的损失。

纯度评价多采用反相高效液相色谱,流动相常加入三氟乙酸或甲酸作为离子对改性剂,检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱,实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成,用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。

Related pages on this site

Background and Drug Class

Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.

Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.

Notes from published material

1980: Japanese geochemist Katsuko Saruhashi became the first woman elected to the Science Council of Japan. 1980: Nigerian geophysicist Deborah Ajakaiye became the first woman in any West African country to be appointed a full professor of physics. Over the course of her scientific career, she became the first female Fellow elected to the Nigerian Academy of Science, and the first female dean of science in Nigeria. 1981: Vera Rubin was the second female astronomer elected to the National Academy of Science. Beginning her academic career as the sole undergraduate in astronomy at Vassar College, Rubin went on to graduate studies at Cornell University and Georgetown University, where she observed deviations from Hubble flow in galaxies and provided evidence for the existence of galactic superclusters. 1982: Nephrologist Leah Lowenstein became the first female dean of a co-educational medical school in the United States. 1982: British geologist Janet Vida Watson FRS was elected president of the Geological Society of London, the first woman to occupy that position. 1983: American cytogeneticist Barbara McClintock received the Nobel Prize in Physiology or Medicine for her discovery of genetic transposition; she was the first woman to receive that prize without sharing it, and the first American woman to receive any unshared Nobel Prize. 1983: Brazilian agronomist Johanna Döbereiner became a founding Fellow of the World Academy of Sciences.

The two substrates of this enzyme are 3-hydroxyisobutyric acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are methylmalonic acid semialdehyde, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3-hydroxy-2-methylpropanoate:NAD+ oxidoreductase. This enzyme participates in valine, leucine and isoleucine degradation.

Surface anatomy, or superficial anatomy, is the study of anatomical landmarks that can be identified readily from the contours or other reference points on the surface of the body. It is important in human anatomy: with knowledge of superficial anatomy, physicians gauge the position and anatomy of deeper structures. Common names of parts of the human body, from top to bottom:

Sources: en.wikipedia.org

Background from the literature

== Other animals == The interscapular brown adipose tissue is commonly referred to as the hibernating gland. Whilst believed by many to be a type of gland, it is actually a collection of adipose tissues lying between the scapulae of rodentine mammals. Composed of brown adipose tissue and divided into two lobes, it resembles a primitive gland, regulating the output of a variety of hormones. The function of the tissue appears to be involved in the storage of medium to small lipid chains for consumption during hibernation, the smaller lipid structure allowing for a more rapid path of energy production than glycolysis. In studies where the interscapular brown adipose tissue of rats were lesioned, it was demonstrated that the rats had difficulty regulating their normal body-weight. The longest-lived small mammals, bats (30 years) and naked mole rats (32 years), all have remarkably high levels of brown adipose tissue and brown adipose tissue activity. However, brown fat is unlikely to play a role in body temperature regulation of many large-bodied mammals as the UCP1 gene, encoding for the key thermogenic protein of the tissue, has been inactivated in several lineages (e.g. horses, elephants, sea cows, whales and hyraxes). A reduced surface area to volume ratio among large-bodied species decreases heat loss in the cold, diminishing thermogenic demands required to defend body temperatures. UCP1 loss in other species (e.g. pangolins, armadillos, sloths and anteaters) may be linked to selection pressures favouring low metabolic rates.

An electronic cigarette consists of an atomizer, a power source such as a battery, and a container for e-liquid such as a cartridge or tank. E-cigarettes come in many shapes and sizes, including disposable devices, refillable devices, and devices with pre-filled cartridges or pods. E-cigarettes have evolved over time, and the different designs are classified in generations. First-generation e-cigarettes tend to look like traditional cigarettes and are called "cigalikes". Second-generation devices are larger and look less like traditional cigarettes. Third-generation devices include mechanical mods and variable voltage devices. The fourth-generation includes sub-ohm tanks (meaning they have electrical resistance of less than 1 ohm) and temperature control. There are also pod mod devices that use protonated nicotine, rather than free-base nicotine found in earlier generations, providing higher nicotine yields. Some electronic cigarettes contain synthetic nicotine analogues (for example, 6-methyl nicotine, sometimes marketed under the trade name "Metatine") and makers are trying develop nicotine substitutes.

Aromatic L-amino acid decarboxylase (AADC or AAAD), also known as DOPA decarboxylase (DDC), tryptophan decarboxylase, and 5-hydroxytryptophan decarboxylase, is a lyase enzyme (EC 4.1.1.28), located in region 7p12.2-p12.1.

Sources: en.wikipedia.org

Frequently asked questions

How is semaglutide administered?

It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.

What distinguishes this molecule from earlier GLP-1 agonists?

Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.

Is the mechanism fully understood?

The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.

Semaglutide 与天然 GLP-1 的主要差别是什么?

差别集中在三处:第 8 位残基被非天然氨基酸取代,第 34 位换成精氨酸,第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率,侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。

Network